MARAC Statement: Pfizer Inclacumab Announcement
August 15, 2025 – In a statement issued today, Pfizer announced the results of their Phase 3 THRIVE-131 study evaluating inclacumab.... Continue Reading
SCDAA’s CHW Training Program Accredited by Maryland
Exciting News: the Maryland Department of Health has officially accredited SCDAA’s Community Health Worker Training! This accolade will allow our program... Continue Reading
In Memory of James E. Rawlings
With great sadness, SCDAA shares the news of the passing of James E. Rawlings, president and CEO of Michelle’s House (SCDAA,... Continue Reading
Black History Month 2025: Dr. Charles F. Whitten
Our first #SCDHistoryHighlight for Black History Month brings attention to the life and work of SCDAA co-founder Dr. Charles F. Whitten. Dr.... Continue Reading
SCDAA Statement on Recent Natural Disasters
SCDAA stands in solidarity with the warriors, advocates and community-based organizations who have been recently affected by natural disasters, including the... Continue Reading
SCDAA names board officers
The Sickle Cell Disease Association of America Inc., a national nonprofit membership organization that advocates for people affected by sickle cell... Continue Reading
MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal... Continue Reading
Sickle Cell Disease is Not a Joke
This weekend’s Saturday Night Live skit about the recent historic approvals of potentially curative gene therapies for sickle cell disease is... Continue Reading
SCDAA Statement About Gene Therapy Approval
On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy... Continue Reading
Gene Therapy is Approved!
We are very excited to share that today, Dec. 8, the Food and Drug Administration approved two gene therapies to treat... Continue Reading